Logo image of TXG

10X GENOMICS INC-CLASS A (TXG) Stock Fundamental Analysis

NASDAQ:TXG - Nasdaq - US88025U1097 - Common Stock - Currency: USD

12.8  +0.18 (+1.43%)

After market: 12.5 -0.3 (-2.34%)

Fundamental Rating

4

Taking everything into account, TXG scores 4 out of 10 in our fundamental rating. TXG was compared to 55 industry peers in the Life Sciences Tools & Services industry. While TXG has a great health rating, there are worries on its profitability. TXG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TXG had negative earnings in the past year.
TXG had a positive operating cash flow in the past year.
TXG had negative earnings in each of the past 5 years.
In the past 5 years TXG reported 4 times negative operating cash flow.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

TXG has a Return On Assets (-17.38%) which is in line with its industry peers.
With a Return On Equity value of -22.21%, TXG perfoms like the industry average, outperforming 52.73% of the companies in the same industry.
Industry RankSector Rank
ROA -17.38%
ROE -22.21%
ROIC N/A
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 68.36%, TXG belongs to the top of the industry, outperforming 96.36% of the companies in the same industry.
TXG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TXG has been increased compared to 1 year ago.
TXG has more shares outstanding than it did 5 years ago.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 3.07 indicates that TXG is not in any danger for bankruptcy at the moment.
TXG's Altman-Z score of 3.07 is fine compared to the rest of the industry. TXG outperforms 61.82% of its industry peers.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.07
ROIC/WACCN/A
WACC10.6%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 5.37 indicates that TXG has no problem at all paying its short term obligations.
TXG has a better Current ratio (5.37) than 72.73% of its industry peers.
A Quick Ratio of 4.68 indicates that TXG has no problem at all paying its short term obligations.
The Quick ratio of TXG (4.68) is better than 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 5.37
Quick Ratio 4.68
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

TXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.12%, which is quite impressive.
The Revenue has decreased by -0.12% in the past year.
TXG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.96% yearly.
EPS 1Y (TTM)38.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
Revenue 1Y (TTM)-0.12%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%9.84%

3.2 Future

TXG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.63% yearly.
The Revenue is expected to grow by 4.34% on average over the next years.
EPS Next Y19.92%
EPS Next 2Y17.55%
EPS Next 3Y15.57%
EPS Next 5Y17.63%
Revenue Next Year-2.6%
Revenue Next 2Y1.64%
Revenue Next 3Y4%
Revenue Next 5Y4.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TXG. In the last year negative earnings were reported.
Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, TXG is valued a bit cheaper than the industry average as 65.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 35.53
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

TXG's earnings are expected to grow with 15.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.55%
EPS Next 3Y15.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TXG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

10X GENOMICS INC-CLASS A

NASDAQ:TXG (7/11/2025, 8:00:02 PM)

After market: 12.5 -0.3 (-2.34%)

12.8

+0.18 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners101.16%
Inst Owner Change0.03%
Ins Owners1.72%
Ins Owner Change19.42%
Market Cap1.58B
Analysts73.64
Price Target13.42 (4.84%)
Short Float %12.41%
Short Ratio3.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.03%
Min EPS beat(2)-34.43%
Max EPS beat(2)24.36%
EPS beat(4)3
Avg EPS beat(4)9.2%
Min EPS beat(4)-34.43%
Max EPS beat(4)33.83%
EPS beat(8)4
Avg EPS beat(8)-9.45%
EPS beat(12)6
Avg EPS beat(12)-5.35%
EPS beat(16)8
Avg EPS beat(16)-4.96%
Revenue beat(2)2
Avg Revenue beat(2)9.14%
Min Revenue beat(2)2.51%
Max Revenue beat(2)15.77%
Revenue beat(4)3
Avg Revenue beat(4)3.48%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)15.77%
Revenue beat(8)5
Avg Revenue beat(8)2.02%
Revenue beat(12)8
Avg Revenue beat(12)1.73%
Revenue beat(16)11
Avg Revenue beat(16)1.2%
PT rev (1m)-12.52%
PT rev (3m)-19.23%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)3.26%
EPS NY rev (1m)9.27%
EPS NY rev (3m)19.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.9%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)-3.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.52
P/FCF 35.53
P/OCF 27.78
P/B 2.23
P/tB 2.29
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)0.36
FCFY2.81%
OCF(TTM)0.46
OCFY3.6%
SpS5.07
BVpS5.74
TBVpS5.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.38%
ROE -22.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.36%
FCFM 7.1%
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
F-Score7
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 35.66%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.37
Quick Ratio 4.68
Altman-Z 3.07
F-Score7
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)231.92%
Cap/Depr(5y)289.86%
Cap/Sales(3y)11.9%
Cap/Sales(5y)13.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
EPS Next Y19.92%
EPS Next 2Y17.55%
EPS Next 3Y15.57%
EPS Next 5Y17.63%
Revenue 1Y (TTM)-0.12%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%9.84%
Revenue Next Year-2.6%
Revenue Next 2Y1.64%
Revenue Next 3Y4%
Revenue Next 5Y4.34%
EBIT growth 1Y25.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.15%
EBIT Next 3Y21.69%
EBIT Next 5Y15.85%
FCF growth 1Y135.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y434.95%
OCF growth 3YN/A
OCF growth 5Y-28.08%